Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Jane Koo(Cincinnati Children's Hospital Medical Center), Christopher E. Dandoy(Cincinnati Children's Hospital Medical Center), Leslie Lehmann(Harvard University), Seth J. Rotz(Cleveland Clinic), Loretta Parker(University of Oklahoma Medical Center), John Huber(Cincinnati Children's Hospital Medical Center), Katilyn Kusnier(University of Cincinnati Medical Center), David Hartley(Cincinnati Children's Hospital Medical Center), Christine Sper(University of Cincinnati Medical Center), Malika Kapadia(Harvard University), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jeffery J. Auletta(Nationwide Children's Hospital), Joseph Maakaron(The Ohio State University), Ahna L. H. Pai(University of Cincinnati Medical Center), Rachel Phelan(Children's Hospital of Wisconsin), Kasiani C. Myers(Immune Deficiency Foundation)
Transplantation and Cellular Therapy
July 25, 2022
10.1016/j.jtct.2022.07.020
Cited by 8

Related Papers

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Rural Health Disparities, Population Health, and Rural Culture
|American Journal of Public Health|2004|769
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US
|JAMA|2020|517